Skip to content

Colorectal Cancer Health Center

Font Size

Stage IV and Recurrent Colon Cancer Treatment

    continued...

    5-FU

    When 5-FU was the only active chemotherapy drug, trials in patients with locally advanced, unresectable, or metastatic disease demonstrated partial responses and prolongation of the time-to-progression (TTP) of disease [41,42] as well as improved survival and quality of life for patients receiving chemotherapy, compared with the best supportive care.[43,44,45] Several trials have analyzed the activity and toxic effects of various 5-FU-leucovorin regimens using different doses and administration schedules and showed essentially equivalent results with a median survival time in the 12-month range.[46]

    Capecitabine

    Prior to the advent of multiagent chemotherapy, two randomized studies demonstrated that capecitabine was associated with equivalent efficacy when compared with the Mayo Clinic regimen of 5-FU-leucovorin.[47,48][Level of evidence: 1iiA]

    Irinotecan

    Three randomized studies demonstrated improved response rates, PFS, and OS when irinotecan or oxaliplatin was combined with 5-FU-leucovorin.[49,50,51]

    Evidence (irinotecan):

    1. An intergroup study (NCCTG-N9741) compared IFL with FOLFOX4 in first-line treatment for patients with metastatic colorectal cancer.
      • Patients assigned to FOLFOX4 experienced an improved PFS (median, 6.9 months vs. 8.7 months; P = .014; hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.61–0.89) and OS (15.0 months vs. 19.5 months, P = .001; HR, 0.66; 95% CI, 0.54–0.82) compared with patients randomly assigned to IFL.[Level of evidence: 1iiA]
    2. Subsequently, two studies compared FOLFOX with FOLFIRI, and patients were allowed to cross over upon progression on first-line therapy, respectively.[52,53][Level of evidence: 1iiDiii]
      • PFS and OS were identical between the treatment arms in both studies.
    3. The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (BICC-C) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer, including FOLFIRI, mIFL, and Capecitabine/irinotecan (CAPIRI).[54][Level of evidence: 1iiA]
      • The study randomly assigned 430 patients and was closed early due to poor accrual.
      • The patients who received FOLFIRI had a better PFS than the patients who received either mIFL (7.6 months vs. 5.9 months, P = .004) or CAPIRI (7.6 months vs. 5.8 months, P = .015).
      • Patients who received CAPIRI had the highest grade 3 or higher rates of nausea, vomiting, diarrhea, dehydration, and hand-foot syndrome.
    1|2|3|4|5|6|7|8|9

    Today on WebMD

    Colorectal cancer cells
    The right diagnosis is the most important factor.
    man with a doctor
    Our health check will steer you in the right direction.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    bladder cancer x-ray
    Do you know the warning signs?
     
    bread
    ARTICLE
    Colon vs Rectal Cancer
    VIDEO
     
    New Colorectal Treatments
    VIDEO
    can lack of sleep affect your immune system
    FEATURE
     
    Cancer Facts Quiz
    QUIZ
    Virtual Colonoscopy
    VIDEO
     
    Picture of the Colon
    ANATOMY
    Vitamin D
    SLIDESHOW
     

    WebMD Special Sections